Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

NCT07691203 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)
Cardiovascular Diseases

Interventions

DRUG: Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet
DRUG: Trijardy® XR Tablets

Sponsor

Humanis Saglık Anonim Sirketi